SCHEMBL6492005

SCHEMBL6492005

Cc1nc2cc(CCl)c(Cl)cc2n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 1/20 0.49
RAB9A P51151 8/20 0.43
NPC1 O15118 7/20 0.43
MAPT P10636 2/20 0.42
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
DCTPP1 Q9H773 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
TP53 P04637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GFER P55789 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501812 0.85 KDM4E (0.47) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL4882909 0.82 KDM4E (0.58) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL24463160 0.76 KDM4E (0.51) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL23302246 0.76 KDM4E (0.51) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL30390474 0.76 KDM4E (0.51) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL26661686 0.75 KDM4E (0.47) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL13916682 0.75 KDM4E (0.69) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL15233269 0.74 KDM4E (0.53) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL13916685 0.73 KDM4E (0.67) KDM4EALDH1A1LMNARAB9ANPC1
SCHEMBL13035825 0.73 KDM4E (0.49) KDM4EALDH1A1LMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A KDM4E 1599/4885ALDH1A1 476/4885LMNA 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.